Opthea Appoints Fred Guerard as CEO and Peter Lang as CFO

Opthea announced that their Chief Executive Officer, Dr. Megan Baldwin, will undertake the role of Founder and Chief Innovation Officer, effective immediately. This transition aligns with the company's strategy to enhance its presence in the United States and globally, particularly in relation to the commercialization of sozinibercept (OPT-302).

In conjunction with this development, Opthea is delighted to introduce two U.S.-based executives, Dr. Frederic Guerard as the new Chief Executive Officer and Peter Lang as the Chief Financial Officer.

Dr. Frederic Guerard and Peter Lang are both esteemed figures in the healthcare industry, known for their track record in establishing and expanding organizations, steering research and development initiatives, leading commercial operations, managing financial matters, and providing strategic guidance. They have successfully navigated companies through pivotal stages of corporate, clinical, and commercial growth.

Fred Guerard, Chief Executive Officer of Opthea, said “I’m excited to join Opthea at such an important time for the Company. I believe it’s now well-positioned to disrupt the eye disease treatment landscape highlighted by sozinibercept’s potential to become the first drug, when used in combination, to deliver superior visual gains compared to standard of care in wet AMD.  I wish to extend my gratitude to the Board for this opportunity and look forward to working with Megan, Peter and the entire team as we work to advance Opthea to ultimately become a premier ophthalmology company.”

Peter Lang added, “I am honored to have this opportunity to work with Fred, Megan, the management team, and Board to efficiently grow the business and bring significant value to patients, clinicians, and investors. The Opthea team continues to build a unique biotech and realize the full potential of its pipeline with a differentiated, first-in-class product candidate in the late stage of pivotal Phase 3 clinical trials addressing a real need for wet AMD patients.”